Neuberger Next-Generation Connectivity Fund: An Enhanced Outlook
Finance

Neuberger Next-Generation Connectivity Fund: An Enhanced Outlook

authorBy Nouriel Roubini
DateMay 10, 2026
Read time2 min

The Neuberger Next-Generation Connectivity Fund (NBXG) has seen its rating elevated to 'Buy'. This fund presents an appealing investment opportunity, trading at a substantial 14.92% discount relative to its Net Asset Value (NAV) and offering a generous 9.4% yield. NBXG's carefully curated portfolio, which incorporates a disciplined approach to option writing and strategic private investments, has consistently surpassed the total return performance of conventional index-linked covered call funds. Despite its robust income generation capabilities, the fund's operational framework, emphasizing distributions, carries an inherent risk of accelerating NAV erosion during prolonged periods of market decline. Consequently, NBXG is particularly suited for investors prioritizing income, who also stand to benefit from its tax-efficient distribution structure. However, it is anticipated that the fund's long-term performance may lag behind broader market indices.

NBXG provides investors with an efficient avenue for instant diversification within the rapidly evolving mobile network connectivity and technology sectors. In a prior assessment, the fund's rating was downgraded, reflecting concerns about its portfolio structure. This reassessment, however, highlights an improved outlook. The fund's ability to maintain a high yield while trading below its intrinsic value makes it a noteworthy option for those seeking regular income streams.

The fund’s investment strategy, characterized by a handpicked selection of assets and a cautious approach to options, has been a key differentiator. This has allowed NBXG to achieve favorable returns even when compared to other funds employing similar income-generating strategies. The inclusion of private investments further contributes to its unique risk-return profile, offering exposure to less liquid but potentially high-growth opportunities within the connectivity landscape.

While NBXG’s focus on distributing income is a significant draw for many investors, it’s crucial to understand the implications for capital preservation, especially in challenging market conditions. The fund's structure is designed to prioritize consistent payouts, which can sometimes come at the expense of its underlying asset value during extended periods of market stress. This trade-off between high yield and potential capital erosion is a critical consideration for prospective investors.

In summary, the Neuberger Next-Generation Connectivity Fund offers an attractive proposition for income-oriented investors, providing diversified exposure to key technology sectors with a substantial yield and NAV discount. Its active management and strategic investment choices have yielded strong performance relative to passive alternatives. Nevertheless, investors should remain cognizant of the fund's structural characteristics, which, while beneficial for income, may pose long-term challenges to capital appreciation when benchmarked against broader market indices.

More Articles
Finance
Reaves Utility Income Fund: A Strategic Play on Data Center Growth and Electricity Demand
The Reaves Utility Income Fund (UTG) is strategically positioned to capitalize on the increasing demand for electricity, driven by the expansion of data centers. Its actively managed portfolio, focused on key companies in the electricity sector, aims for substantial upside potential and offers an attractive distribution yield. The fund's past performance indicates its ability to surpass both market and peer returns, though its success hinges on the sustained growth of data center infrastructure.
By Suze OrmanMay 10, 2026
Finance
Berkshire Hathaway's Investment Strategy and Future Prospects
This article delves into Berkshire Hathaway's current valuation, investment strategy, and future outlook. It examines why the stock is considered a 'hold' despite the potential for generational wealth creation under Greg Abel's leadership. The analysis highlights concerns about Berkshire's trading at 1.4x book value, significant cash reserves, and recent underperformance. It also explores the impact of the 'Warren Buffett premium' evaporation and limited tech exposure, suggesting that a market correction could present a favorable buying opportunity.
By Nouriel RoubiniMay 10, 2026
Finance
Colgate-Palmolive: A Defensive Stock at a Premium Price
Colgate-Palmolive (CL) recently announced its first-quarter 2026 earnings, revealing an 8% increase in sales but a 6% decline in EPS. This article analyzes the underlying factors contributing to these mixed results, highlighting the impact of foreign exchange tailwinds on international growth and the challenges posed by increased competition and elevated input costs in the North American market.
By Fareed ZakariaMay 10, 2026
Finance
Global Market Dynamics: Currencies, Commodities, and Central Bank Policies
This article analyzes recent fluctuations in global financial markets, focusing on currency movements (Euro, USD, JPY, NOK, MXN) and commodity prices (WTI, Brent crude). It explores the impact of central bank decisions, geopolitical events, and economic indicators on market sentiment, highlighting the interconnectedness of these factors in shaping the international financial landscape.
By Nouriel RoubiniMay 10, 2026
Finance
Krystal Biotech: Beyond VYJUVEK - Unlocking Future Growth Potential
Krystal Biotech (KRYS) is making significant strides with its HSV-1 gene delivery platform, notably with VYJUVEK, which has achieved strong market performance and high gross margins since its FDA approval. The company's future growth is underpinned by a robust pipeline, especially the promising oncology asset KB707, and a substantial cash reserve of $1 billion, ensuring continued R&D investment without shareholder dilution. VYJUVEK's global expansion and upcoming pipeline milestones are projected to boost annual net income substantially, with a potentially attractive forward P/E ratio. While dependency on VYJUVEK and clinical trial outcomes present risks, a diversified pipeline and expedited regulatory pathways mitigate these concerns, reinforcing the long-term investment thesis.
By Suze OrmanMay 10, 2026